NASDAQ:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free BRTX Stock Alerts $1.16 -0.02 (-1.69%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share Today's Range$1.14▼$1.2050-Day Range$1.16▼$1.4852-Week Range$1.13▼$7.13Volume21,700 shsAverage Volume571,085 shsMarket Capitalization$7.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1,981 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.96) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for BioRestorative Therapies.Read more about BioRestorative Therapies' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.42% of the float of BioRestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBioRestorative Therapies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioRestorative Therapies has recently decreased by 21.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BioRestorative Therapies this week, compared to 0 articles on an average week.Search Interest3 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,981.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioRestorative Therapies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($1.96) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market Moving TrendsTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In About BioRestorative Therapies Stock (NASDAQ:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesJune 4, 2024 | globenewswire.comBioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare ConferenceMay 25, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance NoticeMay 24, 2024 | globenewswire.comBioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance NoticeMay 17, 2024 | seekingalpha.comBioRestorative Therapies reports Q1 resultsMay 15, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 14, 2024 | globenewswire.comBioRestorative Therapies Provides First Quarter 2024 Business UpdateMay 8, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityMay 8, 2024 | globenewswire.comBioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityApril 30, 2024 | globenewswire.comBioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 30, 2024 | globenewswire.comBioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics TechnologyApril 16, 2024 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol AmendmentApril 16, 2024 | theglobeandmail.comBiotech Catches Major Premarket Bid Following FDA ClearanceApril 16, 2024 | marketwatch.comBioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol AmendmentApril 16, 2024 | msn.comBioRestorative gains as FDA clears amendment to study on cell therapy candidateApril 16, 2024 | globenewswire.comBioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol AmendmentApril 12, 2024 | investing.comBioRestorative Therapies VP buys shares worth over $10,000April 8, 2024 | globenewswire.comBioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc DiseaseApril 3, 2024 | globenewswire.comBioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued WarrantsApril 3, 2024 | finance.yahoo.comBioRestorative Therapies Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | globenewswire.comBioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-KMarch 12, 2024 | msn.comBioRestorative engages advisory firm for clinical application of cell therapy BRTX-100March 11, 2024 | globenewswire.comBioRestorative Therapies to Participate in the 36th Annual ROTH ConferenceFebruary 15, 2024 | finance.yahoo.comFavourable Signals For BioRestorative Therapies: Numerous Insiders Acquired StockFebruary 14, 2024 | finance.yahoo.comBioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual MeetingFebruary 9, 2024 | msn.comBioRestorative Therapies Sparks Investor Interest with New TransactionSee More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,410,000.00 Net Margins-9,873.97% Pretax Margin-9,886.83% Return on Equity-114.84% Return on Assets-107.19% Debt Debt-to-Equity RatioN/A Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual Sales$150,000.00 Price / Sales52.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.47Miscellaneous Outstanding Shares6,770,000Free Float5,308,000Market Cap$7.85 million OptionableNot Optionable Beta61.71 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $954.17kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $368.12kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $891.67kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsOntrakNASDAQ:OTRKMangoceuticalsNASDAQ:MGRXMarpaiNASDAQ:MRAIGreenbrook TMSNASDAQ:GBNHFGlobal Cord BloodNYSE:CORBFView All CompetitorsInsiders & InstitutionsStoneX Group Inc.Bought 34,850 shares on 5/1/2024Ownership: 0.515%Francisco SilvaBought 1,708 shares on 4/8/2024Total: $1,981.28 ($1.16/share)Dale BroadrickBought 86,041 shares on 2/9/2024Total: $113,574.12 ($1.32/share)Dale BroadrickBought 36,374 shares on 2/7/2024Total: $50,196.12 ($1.38/share)Dale BroadrickSold 250 sharesTotal: $470.00 ($1.88/share)View All Insider TransactionsView All Institutional Transactions BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 at the beginning of the year. Since then, BRTX stock has decreased by 33.3% and is now trading at $1.16. View the best growth stocks for 2024 here. Are investors shorting BioRestorative Therapies? BioRestorative Therapies saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 132,600 shares, a decline of 21.8% from the April 30th total of 169,600 shares. Based on an average trading volume of 535,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.4% of the shares of the stock are sold short. View BioRestorative Therapies' Short Interest. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (NASDAQ:BRTX) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.57) earnings per share for the quarter. The company earned $0.02 million during the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 9,873.97% and a negative trailing twelve-month return on equity of 114.84%. Who are BioRestorative Therapies' major shareholders? BioRestorative Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include StoneX Group Inc. (0.51%). Insiders that own company stock include Dale Broadrick, Francisco Silva and Lance Alstodt. View institutional ownership trends. How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BRTX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.